Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: Current status and future directions

Keyphrases

• Glycoprotein IIb/IIIa Inhibitors 100%
• Acute Ischemic Stroke 100%
• Stroke Current 100%
• Abciximab 75%
• Heparin 50%
• Phase II Trial 50%
• Platelet Inhibition 50%
• Pharmacology 25%
• Thrombosis 25%
• Intra-arterial 25%
• Potential Gains 25%
• Aspirin 25%
• Acute Coronary Syndrome 25%
• Coronary Disease 25%
• Mechanism of Action 25%
• Phase I Trial 25%
• Platelets 25%
• Thrombolysis 25%
• Tirofiban 25%
• Clopidogrel 25%
• Preclinical Data 25%
• Coronary Intervention 25%
• Ischemic Stroke 25%
• Stroke Patients 25%
• Eptifibatide 25%
• Glycoprotein IIb/IIIa Receptor 25%
• Risk-benefit Ratio 25%
• Weight-based 25%
• Adjunctive Agent 25%
• Ultra-low Dose 25%
• Potentiation 25%
• Clot Lysis 25%

Medicine and Dentistry

• Brain Ischemia 100%
• Fibrinogen Receptor Antagonist 100%
• Abciximab 75%
• Heparin 50%
• Platelet 50%
• Blood Clot Lysis 50%
• Apoplexy 50%
• Receptor 25%
• Thrombosis 25%
• Acute Coronary Syndrome 25%
• Heart Muscle Ischemia 25%
• Clopidogrel 25%
• Low Drug Dose 25%
• Tirofiban 25%
• Acetylsalicylic Acid 25%
• Fibrinogen Receptor 25%
• Eptifibatide 25%
• Phase I Trials 25%
• Microcirculation 25%
• Phase II Trials 25%
• Thrombocyte Aggregation Inhibition 25%
• Phase III Trials 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Brain Ischemia 100%
• Fibrinogen Receptor Antagonist 100%
• Abciximab 75%
• Heparin 50%
• Cerebrovascular Accident 50%
• Thrombosis 25%
• Receptor 25%
• Acetylsalicylic Acid 25%
• Heart Muscle Ischemia 25%
• Acute Coronary Syndrome 25%
• Clopidogrel 25%
• Phase II Trials 25%
• Phase I Trials 25%
• Fibrinogen Receptor 25%
• Eptifibatide 25%
• Tirofiban 25%
• Phase III Trials 25%